Remicade 100 mg powder for concentrate for solution for infusion.

DRUG4 trials

Sponsors

Biocompatibles UK Limited, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Region Skane, Isala Klinieken Stichting

Conditions

Crohn´s diseaseHepatocellular CarcinomaInflammatory bowel diseaseOncologyRheumatic diseaseRheumatoid arthritis according to 2010 criteriaUlcerative colitis

Phase 2

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

Active, not recruitingCTIS2023-508945-41-00

Biocompatibles UK LimitedHepatocellular Carcinoma

Start: 2023-10-11Target: 81Updated: 2026-01-27

Phase 4

Stopping anti-TNF treatment in Crohn's and Colitis patients in remission

RecruitingCTIS2024-513299-17-00

Region SkaneCrohn´s disease, Ulcerative colitis

Start: 2017-05-05Target: 350Updated: 2024-09-09

PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach

Not yet recruitingCTIS2024-511530-12-01

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rheumatoid arthritis according to 2010 criteria

Target: 300Updated: 2024-10-01

Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)

Not yet recruitingCTIS2024-518878-14-01

Isala Klinieken StichtingInflammatory bowel disease, Oncology, Rheumatic disease

Target: 1261Updated: 2025-12-18